`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`REGENERON PHARMACEUTICALS, INC.,
`Petitioner
`
`v.
`
`NOVARTIS PHARMA AG, NOVARTIS TECHNOLOGY LLC,
`NOVARTIS PHARMACEUTICALS CORPORATION,
`Patent Owners.
`
`Case: IPR2021-00816
`Patent No. 9,220,631
`
`DECLARATION OF JOHN T. BENNETT IN SUPPORT
`OF PATENT OWNERS’ MOTION FOR PRO HAC VICE
`ADMISSION OF JOHN T. BENNETT UNDER 37 C.F.R. § 42.10(c)
`
`1
`
`Novartis Exhibit 2333.001
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`I, John T. Bennett, declare as follows:
`
`1.
`
`I obtained a B.A. from Dartmouth College in 1996 and a J.D. from
`
`Boston College in 2000.
`
`2.
`
`I am currently a partner in the law firm of Allen & Overy LLP. In my
`
`21 years of law practice, I have focused primarily on representing clients in patent
`
`litigations involving the pharmaceutical and chemical arts in United States District
`
`Courts and the Court of Appeals for the Federal Circuit. Through this work, I have
`
`gained extensive experience as a litigating attorney, particularly in patent cases.
`
`3.
`
`I am a member in good standing of the Bar of the Commonwealth of
`
`Massachusetts. I am admitted to practice before the United States District Court for
`
`the District of Massachusetts. I am also admitted to practice before the U.S. Court of
`
`Appeals for the Federal Circuit, the U.S. Court of Appeals for the First Circuit, the
`
`U.S. Court of Appeals for the Fifth Circuit and the U.S. Court of Appeals for Tenth
`
`Circuit.
`
`4.
`
`Within the last three years, I have not appeared pro hac vice before the
`
`Office. However, I have successfully applied to appear pro hac vice before the
`
`Office in the following past proceedings: IPR 2015-00830, IPR 2015-01976, IPR
`
`2015-01980, IPR 2015-01981, IPR 2016-00254.
`
`Novartis Exhibit 2333.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`5.
`
`I have substantial familiarity with the subject matter at issue in this
`
`proceeding. I have developed a strong familiarity with U.S. Patent No. 9,220,631
`
`(“the ’631 patent”), its prosecution history, the general subject matter to which the
`
`’631 patent is directed, and the prior art references relied upon by Petitioner.
`
`Furthermore, I have thoroughly reviewed the Petition and accompanying Exhibits
`
`submitted in this proceeding.
`
`6.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`7.
`
`I have never had an application for admission to practice before any
`
`court or administrative body denied.
`
`8.
`
`I have never been subject to any sanction or contempt citation imposed
`
`by any court or administrative body.
`
`9.
`
`I have read and will comply with the Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trials set forth in part 42 of 37 C.F.R.
`
`10.
`
`I agree to be subject to the USPTO Rules of Professional Conduct set
`
`forth in 37 C.F.R. §§ 11.101 et. seq. and disciplinary jurisdiction under 37 C.F.R.
`
`§11.19(a).
`
`11.
`
`I declare under penalty of perjury that the foregoing is true and
`
`correct. I further declare that all statements made herein of my own knowledge are
`
`true and that all statements made on information and belief are believed to be true;
`
`Novartis Exhibit 2333.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`and further that these statements were made with the knowledge that willful false
`
`statements and the like so made are punishable by fine or imprisonment, or both,
`
`under section 1001 of title 18 of the United States Code, and that such willful false
`
`statements may jeopardize the validity of the application or any patent issued
`
`thereon.
`
`Executed on: March 24, 2022
`
`/John T. Bennett/
`John T. Bennett
`
`Novartis Exhibit 2333.004
`Regeneron v. Novartis, IPR2021-00816
`
`